Strategies of treating cancer by cytokine regulation of chromosome end remodelling

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 1, 2010, Pages 88-92

  Liu, Jun Ping ^a   Nicholls, Craig ^a   Chen, Shi Ming ^b   Li, He ^a   Tao, Ze Zhang ^b  

^a MONASH UNIVERSITY   (Australia)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Cancer; Cytokine; Telomerase; Telomeres; TGF beta family; Therapeutics

Indexed keywords

CYTOKINE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL AGING; CONFERENCE PAPER; ENZYME INHIBITION; GENE SILENCING; HUMAN; NONHUMAN; TELOMERE; TRANSCRIPTION REGULATION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; CELL DIVISION; CYTOKINES; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TELOMERASE; TELOMERE; TRANSFORMING GROWTH FACTOR BETA;

EID: 74049134384     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05251.x     Document Type: Conference Paper

References (56)

1. Blackburn EH. Switching and signaling at the telomere. Cell 2001 106 : 661 673.
2. Reddel RR, Bryan TM. Alternative lengthening of telomeres: Dangerous road less travelled. Lancet 2003 361 : 1840 1841.
3. Wright WE, Tesmer VM, Liao ML, Shay JW. Normal human telomeres are not late replicating. Exp. Cell Res. 1999 251 : 492 499.
4. Griffith JD, Comeau L, Rosenfield S et al. Mammalian telomeres end in a large duplex loop. Cell 1999 97 : 503 514.
5. Szilard RK, Durocher D. Telomere protection. An act of God. Curr. Biol. 2006 16 : R544 6.
6. de Lange T. Protection of mammalian telomeres. Oncogene 2002 21 : 532 540.
7. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 2004 119 : 355 368.
8. Smith CD, Blackburn EH. Uncapping and deregulation of telomeres lead to detrimental cellular consequences in yeast. J. Cell Biol. 1999 145 : 203 214.
9. Tomas-Loba A, Flores I, Fernandez-Marcos PJ et al. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 2008 135 : 609 622.
10. Shay JW, Wright WE. Hallmarks of telomeres in ageing research. J. Pathol. 2007 211 : 114 123.
11. Wang X, Kam Z, Carlton PM, Xu L, Sedat JW, Blackburn EH. Rapid telomere motions in live human cells analyzed by highly time-resolved microscopy. Epigenetics Chromatin 2008 1 : 1 19.
12. Blasco MA, Lee HW, Hande MP et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997 91 : 25 34.
13. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990 345 : 458 460.
14. Olovnikov AM. Principle of marginotomy in template synthesis of polynucleotides. Dokl. Akad. Nauk SSSR 1971 201 : 1496 1499.
15. Watson JD. Origin of concatemeric T7 DNA. Nat. New Biol. 1972 239 : 197 201.
16. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961 25 : 585 621.
17. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002 21 : 598 610.
18. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat. Genet. 2000 26 : 447 450.
19. Muntoni A, Neumann AA, Hills M, Reddel RR. Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum. Mol. Genet. 2009 18 : 1017 1027.
20. Jiang WQ, Zhong ZH, Henson JD, Reddel RR. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 2007 26 : 4635 4647.
21. Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum. Mol. Genet. 2005 2 : R191 6.
22. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999 13 : 2091 2104.
23. Liu JP. Telomerase: Not just black and white, but shades of gray. Mol. Cell Biol. Res. Commun. 2000 3 : 129 135.
24. Liu JP, Cassar L, Pinto A, Li H. Mechanisms of cell immortalization mediated by EB viral activation of telomerase in nasopharyngeal carcinoma. Cell Res. 2006 16 : 809 817.
25. Xu D, Dwyer J, Li H, Duan W, Liu JP. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J. Biol. Chem. 2008 283 : 23567 23580.
26. Bayne S, Jones ME, Li H, Liu JP. Potential roles for estrogen regulation of telomerase activity in aging. Ann. N. Y. Acad. Sci. 2007 1114 : 48 55.
27. Bayne S, Jones ME, Li H, Pinto AR, Simpson ER, Liu JP. Estrogen deficiency leads to telomerase inhibition, telomere shortening and reduced cell proliferation in the adrenal gland of mice. Cell Res. 2008 18 : 1141 1150.
28. Bayne S, Liu JP. Hormones and growth factors regulate telomerase activity in ageing and cancer. Mol. Cell. Endocrinol. 2005 240 : 11 22.
29. Li H, Liu JP. Mechanisms of Action of TGF-beta in cancer: Evidence for Smad3 as a repressor of the hTERT gene. Ann. NY Acad. Sci. 2007 1114 : 56 68.
30. Li H, Xu D, Li J, Berndt MC, Liu JP. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 2006 281 : 25588 25600.
31. Isenmann S, Cakouros D, Zannettino A, Shi S, Gronthos S. hTERT transcription is repressed by Cbfa1 in human mesenchymal stem cell populations. J. Bone Miner. Res. 2007 22 : 897 906.
32. Katakura Y, Nakata E, Miura T, Shirahata S. Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem. Biophys. Res. Commun. 1999 255 : 110 115.
33. Vijayachandra K, Lee J, Glick AB. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res. 2003 63 : 3447 3452.
34. Debacq-Chainiaux F, Borlon C, Pascal T et al. Repeated exposure of human skin fibroblasts to UVB at subcytotoxic level triggers premature senescence through the TGF-beta1 signaling pathway. J. Cell Sci. 2005 118 : 743 758.
35. Li H, Pinto AR, Duan W, Li J, Toh BH, Liu JP. Telomerase down-regulation does not mediate PC12 pheochromocytoma cell differentiation induced by NGF, but requires MAP kinase signalling. J. Neurochem. 2005 95 : 891 901.
36. Hu B, Tack DC, Liu T, Wu Z, Ullenbruch MR, Phan SH. Role of Smad3 in the regulation of rat telomerase reverse transcriptase by TGFbeta. Oncogene 2006 25 : 1030 1041.
37. Stampfer MR, Bodnar A, Garbe J et al. Gradual phenotypic conversion associated with immortalization of cultured human mammary epithelial cells. Mol. Biol. Cell 1997 8 : 2391 2405.
38. Stampfer MR, Garbe J, Levine G, Lichtsteiner S, Vasserot AP, Yaswen P. Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc. Natl Acad. Sci. USA 2001 98 : 4498 4503.
39. Varga AC, Wrana JL. The disparate role of BMP in stem cell biology. Oncogene 2005 24 : 5713 5721.
40. Itman C, Mendis S, Barakat B, Loveland KL. All in the family: TGF-beta family action in testis development. Reproduction 2006 132 : 233 246.
41. Itman C, Loveland KL. SMAD expression in the testis: An insight into BMP regulation of spermatogenesis. Dev. Dyn. 2008 237 : 97 111.
42. Hogan BL. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev. 1996 6 : 432 438.
43. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor "beta" in mesangial cells. J. Biol. Chem. 2004 279 : 23200 23206.
44. Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006 45 : 411 419.
45. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 2004 23 : 9326 9335.
46. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. Diverse biological effect and smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 2005 65 : 5769 5777.
47. Jena N, Martin-Seisdedos C, McCue P, Croce CM. BMP7 null mutation in mice. Developmental defects in skeleton, kidney, and eye. Exp. Cell Res. 1997 230 : 28 37.
48. Cassar L, Li H, Pinto AR, Nicholls C, Bayne S, Liu JP. Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth. Cancer Res. 2008 68 : 9157 9166.
49. Cassar L, Nicholls C, Pinto AR, Li H, Liu JP. Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence and death via smad3. FASEB J. 2009 23 : 1880 1892.
50. Ro TB, Holt RU, Brenne AT et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004 23 : 3024 3032.
51. Buijs JT, Henriquez NV, van Overveld PG et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007 67 : 8742 8751.
52. Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007 13 : 952 961.
53. Buijs JT, Rentsch CA, van der Horst G et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am. J. Pathol. 2007 171 : 1047 1057.
54. Wang Y, Tao ZZ, Chen SM, Xiao BK, Zhou XH, Liu JP. Application of combination of short hairpin RNA segments for silencing VEGF, TERT and Bcl-xl expression in laryngeal squamous carcinoma. Cancer Biol. Ther. 2008 7 : 896 901.
55. Shay JW, Wright WE. Telomerase therapeutics for cancer: Challenges and new directions. Nat. Rev. Drug Discov. 2006 5 : 577 584.
56. Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005 7 : 1 2.